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Abstract
Massive hemoptysis is a stressful and life-threatening event that
can occur in lung cancer patients. The management of this event is
usually challenging, and can involve surgery, embolization, and bron-
choscopy. Unfortunately, while surgery can offer a definitive solution
to hemoptysis, lung cancer patients are often excluded from this ap-
proach. On the other hand, bronchial arterial embolization rarely re-
sults in long-term control of bleeding. 
Endoscopy allows a skilled physician to perform mechanical tam-
ponade or laser photocoagulation of bleeding lesions and preserve
the main airways. While endoscopic stent placement is usually per-
formed in order to treat stenosis, it has been occasionally employed
to isolate and mechanically block the bleeding sites within the
bronchial tree. 
We present the cases of two patients suffering from lung cancer-
related life-threatening hemoptysis; both patients were successfully
treated by positioning a silicone stent during emergency bron-
choscopy. Subsequently, we present a concise review of the available
literature. 
Introduction 
Hemoptysis is an alarming and sometimes dangerous event occur-
ring in 19-32% of lung cancer patients. The reported mortality rate for
mild and moderate hemoptysis is 2.5% and 6%, respectively, while mas-
sive events, albeit uncommon (5-15%) are lethal in 38% of cases; no-
tably, the mortality rate of hemoptysis related to lung cancer is higher
compared to other causes [1]. 
The treatment options for this event include pharmacologic meas-
ures such as antifibrinolytic agents, vascular embolization, endoscopic
procedures, and surgical resection. In particular, endoscopy has a rele-
vant role in the emergency management of massive hemoptysis, as an
urgent rigid bronchoscopy or a flexible bronchoscopy inside a tracheal
tube is efficient in clearing the airways, tamponing the bleeding and
therefore preserving ventilation, provided that the procedure is per-
formed by skilled personnel; however, the long-term efficacy of the
known endoscopic procedures is reportedly limited [2,3].
Here we describe two cases of patients with massive hemoptysis who




The first case report involves a 51-year-old woman affected by ade-
nocarcinoma of the lung; no relevant bleeding diathesis or anticoagu-
lant/antiaggregant treatment was reported. The patient had a large
neoplastic lesion involving the upper right lobe, as well as multiple
small lesions in both lungs, mediastinal lymphoadenopathies, and right
pleural effusion (stage IV). The patient was a former smoker (30
packs/years). The research for actionable mutations of the epidermal
growth factor receptor (EGFR) gene or translocations of the anaplastic
lymphoma kinase (ALK) gene was negative, thus the patient received
a chemotherapy combination of cisplatin plus pemetrexed for 4 cycles;
the treatment was substantially well tolerated, and no significant re-
duction in platelet count was reported. Notably, the patient reported
episodes of mild hemoptysis since the time of the diagnosis. 
Six months after the diagnosis, the patient was referred to the emer-
gency department of the San Martino Hospital - National Institute for
Cancer Research for an episode of moderate hemoptysis, where a com-
puted tomography (CT)-scan showed increase of the tumor mass in the
right upper lobe with involvement of the right upper lobe bronchus with
occlusion of its ostium; the invading neoplastic tissue was treated with
endoscopic laser photocoagulation (diode laser), resulting in marked
reduction of the bleeding.
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Case 2
The second case involves a 78-year-old male former smoker (40
pack/years) affected by a squamous cell carcinoma in the lower lobe of
the right lung; no relevant bleeding diathesis or anticoagulant/antiag-
gregant treatment was reported. Due to the size of the tumor, the pa-
tient was excluded from curative surgery and therefore considered el-
igible for chemotherapy followed by thoracic radiation therapy. The pa-
tient received 2 cycles of carboplatin plus etoposide from August 2015
to September 2015, followed by a CT-scan showing progressive disease
in the right lung; for this reason, the planned radiation therapy was
omitted and the patient received second-line treatment with
Nivolumab.
Since February 2016, the patient had been suffering from episodic
blood-tinged sputum; in June 2016, a progressive worsening of the
bleeding was observed, until he had to be taken to the emergency
room for an episode of massive hemoptysis. During bronchoscopy, an
evident intra-bronchial disease progression was observed, with
bleeding neoplastic tissue reaching the entrance of the intermediate
bronchus. A diode laser photocoagulation therapy was performed
using a flexible bronchoscope, but it did not prove sufficiently effec-
However, three weeks later, the patient was hospitalized for a new
hemoptysis episode; while the episode was initially described as mas-
sive, when the patient was referred to our pulmonology unit, the
bleeding was significantly reduced and did not require emergency
treatment; therefore, other therapeutic options were considered. A sur-
gical palliative procedure was excluded because the neoplasm involved
the thoracic great vessels and the right tracheobronchial angle; hence,
a transcatheter embolization was performed by the staff of the inter-
ventional radiology unit, leading to significant reduction of bleeding. 
One week later, while the patient was still hospitalized in the pul-
monology unit after the radiologic procedure, she suffered from an
episode of massive hemoptysis, which led to acute respiratory failure.
The patient immediately underwent an emergency intubation with a
rigid bronchoscope; during the procedure, mechanical tamponade and
a diode laser photocoagulation of the bleeding source were performed
while the airways were kept patent, thus preserving ventilation. In
order to prevent further episodes of hemoptysis, a silicone stent 13x30
mm was inserted in the right main bronchus, occluding the entrance of
the right upper lobe bronchus (Figure 1). The procedure was effective,
as no further bleeding episodes were observed. Two months later, the
patient died due to disease progression.
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Figure 1. Relevant images of the Case Report 1. A) Coronal and B) sagittal CT scans after insertion of the silicone stent. C) Dumon stent
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tive in stopping the bleeding. On the basis of the experience that had
been developed in the previous case, the decision of inserting a stent
in order to stop the hemorrhage was taken. However, at that time a
suitable closed distal stent was not readily available in the pul-
monology unit; hence, a 13x25 mm silicone stent was closed in its
distal part with a suture thread and subsequently positioned in the in-
termediate bronchus to apply a mechanical tamponade (Figure 2).
The procedure was immediately effective and no more hemoptysis
episodes were reported; after the hospitalization, the patient resumed
its planned anti-neoplastic treatment and he is currently receiving
Nivolumab.
Discussion
Hemoptysis is a common symptom in lung cancer and is the terminal
event in 3% of the cases. Hemoptysis often increases with the progres-
sion of the disease and in particular in the endoscopic progression. The
presence of hemoptysis greatly impacts the quality of life of lung cancer
patients; even episodes of mild or moderate hemoptysis are often per-
ceived as stressful events and imply the possibility of a massive
bleeding, which is always a dangerous and frightening occurrence for
the patients and requires prompt medical intervention. To date there is
no clear consensus on the definition of massive hemoptysis. Currently,
rather than using a quantitative definition, it is preferred to define
massive hemoptysis based on its clinical consequences, such as respi-
ratory failure and hemodynamic instability [4].
Massive hemoptysis in patients with advanced thoracic malignan-
cies can be difficult to manage, due to the global conditions of the pa-
tients and cancer-related comorbidities; in such cases, bleeding can be
caused by necrosis of a tumor, rupture of small blood vessels in the
area, or tumor invading one of the pulmonary blood vessels [5]. In such
cases, the first step is to define the site of hemorrhage, as this infor-
mation is critical for the subsequent steps; a CT scan can locate the site
of bleeding in 70-88% of cases [6]. As one might expect, respiratory
and hemodynamic conditions affect the patient’s course and need to be
promptly managed. If marked bleeding causes acute respiratory failure,
an endoscopic procedure with rigid bronchoscope performed by skilled
personnel is required, as it allows the physician to remove blood and
clots, use blocking devices as the balloon, and to perform mechanical
tamponade, thus preserving ventilation. In the current clinical practice,
however, not all bronchoscopists are able to use a rigid bronchoscope;
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Figure 2. Relevant images of the Case Report 2. A) Coronal and B) sagittal CT scans after insertion of the silicone stent. C) Modified
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An additional research using ‘hemoptysis’ and ‘silicone stent’ showed
a single publication [10]. The global number of published cases is re-
ported in Table 1. The total number of reported patients, including our
cases, is 8. The median age at the time of the procedure was 62 years
(range: 46-78), and the male/female ratio is 6:2; all the reported cases
were affected by non-small cell lung cancer, but the exact histology was
defined only in 4 cases (1 adenocarcinoma and 3 squamous cell carci-
nomas). Only 3 out of 8 patients had received other treatments for he-
moptysis before undergoing stent placement. The median time from di-
agnosis of lung cancer to treatment with stents was 12 months (range:
5-17 months), excluding a case where the bleeding was iatrogenic (fol-
lowing a bronchial biopsy). In 5 cases, a covered nitinol stent was em-
ployed, while in another case a Y-silicone stent was placed on a sec-
ondary carina and straight silicone stents were placed in the two cases
managed within our institution. In six cases, the stent placement re-
sulted in bleeding cessation; in one case, the bleeding was only briefly
reduced and, ultimately, the treatment was not considered effective.
The median survival after stent insertion was 90 days (range: 2-120
days). In six patients, hemoptysis was not the cause of death, and one
patient is currently alive [5,10-12].
Conclusions
In our opinion, based on the experience developed within our in-
stitution and on the available publications, endobronchial stent place-
ment, whether made of metal or silicone, should be considered a suit-
able and potentially resolution option for the management of mod-
erate/severe and recurrent hemoptysis. While both metal and silicone
stents have been used for this purpose, our experience suggests that
silicone stents are more manageable, as they can be promptly and
successfully adapted to the bleeding site in the tracheobronchial tree
(as reported in our second case).
by consequence, during a massive hemoptysis it is necessary to intu-
bate the patient with an endotracheal tube using a flexible broncho-
scope. In most cases, endobronchial tamponade offers only temporary
relief and does not result in long-term benefit [7]. Bronchial artery em-
bolization (BAE) is a therapeutic modality for life-threatening massive
hemoptysis. This modality has revolutionized management of these
events, being a less invasive but reliable procedure that leads to excel-
lent short-term therapeutic outcomes (immediate decrease or resolu-
tion of bleeding in most cases) [8]. If needed, BAE can be repeated
multiple times; however, bleeding relapse is very frequent in cancer pa-
tients, whose prognosis remains poor [9]. Another possible option for
severe hemoptysis is surgery; this procedure is often resolutive, as it is
meant to remove the bleeding cause, but its applicability in the case of
lung cancer patients is extremely limited due to technical difficulties
and the general conditions of oncologic patients. 
In 2010, Sakr and Dutau published an update on the role on the
bronchoscopic management of massive hemoptysis [3]. In this publi-
cation, they proposed a management algorithm in which the choice
between BAE and surgery is the last step after more conservative ap-
proaches [3]. However, in a significant number of cases, BAE was in-
effective and surgery was not feasible; therefore, other therapeutic op-
tions are highly advised in this setting. During bronchoscopy,
bronchial stents are normally intended to recanalize the airway in
case of neoplastic obstruction and only few published cases involve
their use with the aim of tamponing a neoplastic hemorrhage. In the
two reported cases, tamponade with a silicone stent in two different
sites, led to the definitive cessation of bleeding; in the second case,
the modified silicone stent was effective and even allowed the patient
to resume his systemic anti-neoplastic treatments. 
In order to identify the available literature, we performed a PubMed
research using the following parameters: (‘endobronchial stent’ OR
‘airway stent’) AND (‘hemoptysis’ OR ‘bleeding’ OR ‘hemorrhage’); 20
publications were found, only 3 of them actually related to the subject.
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Table 1. Patient and treatment characteristics.
Author Gender Histology Previous Time from Tumor Stent Stent Stop Survival 
Year Age hemoptysis diagnosis site (mm) site bleeding (days)
treatment (months)
Brandes 2008 [11] F 72 NSCLC – 17 LLL Poliflex 8x20 LLL Yes 120
CN stent LMB-LUL
14x60
Chung 2010 [12] M 49 SCC – 5 LMB CN stent LMB Partial 90




Lee 2011 [5] M 72 SCC – 20 LMB CN stent LMB Yes 16
12x53




Dalar 2014[10] M 52 NSCLC – Iatrogenic LUL Y silicon stent LMB-LLL-LUL Yes 90
14x10x10
This study 2016 F 51 ADC RT - 6 RUL S stent IB-RMB Yes 60
Laser-BAE 13x30
This study 2016 M 78 SCC Laser 12 RLL S stent IB Yes AWD (70)
13x25
F: female; M: male; NSCLC: non-small cell lung cancer; SCC: squamous cell carcinoma; ADC: adenocarcinoma; RT: radiotherapy; LLL: left lower lobe; LMB: left main bronchus; RUL: right upper lobe; LUL: left upper










[Monaldi Archives for Chest Disease 2017; 87:781] [page 69]
Case Report
References
1. Hirshberg B, Niran I, Glazer M. Hemoptysis: etiology, evaluation,
and outcome in a tertiary referral hospital. Chest 1997;112:440-4.
2. Milani GF, Simonassi C, Salio M. Palliative therapy. Monaldi Arch
Chest Dis 2011;75:72-7.
3. Sakr L, Dutau H. Massive hemoptysis: an update on the role of
bronchoscopy in diagnosis and managemen. Respiration 2010;80:
38-58.
4. Kvale PA, Selecky PA, Prakash UB. American College of Chest
Physician. Palliative care in lung cancer: ACCP evidence-based
clinical practice guidelines (2nd edition). Chest 2007;132:
S368-403.
5. Lee SA, Kim DH, Jeon GS. Covered bronchial stent insertion to
manage airway obstruction with hemoptysis caused by lung cancer.
Korean J Radiol 2012;13:515-20.
6. Khalil A, Soussan M, Mangiapan CG, et al. Utility of high resolution
chest CT scan in the emergency management of hemoptysis in the
intensive care unit: severity, localization and aetiology. Br J Radiol
2007;80:21-5.
7. Dweik RA, Stoller JK. Role of bronchoscopy in massive hemoptysis.
Clin Chest Med 1999;20:89-105.
8. Hayakawa K, Tanaka F, Torizuka T, et al. Bronchial artery emboliza-
tion for hemoptysis: immediate and long term results. Cardiovasc
Interv Radiol 1992;15:154-9.
9. Wang GR, Ensor JE, Gupta S, et al. Bronchial artery embolization
for the management of hemoptasis in oncology patients: utility and
prognostic factors. J Vasc Interv Radiol 2009;20:722-9.
10. Dalar L, Ozdemir C, Sokucu S, et al. The management of near-fatal
hemoptysis with left secondary carinal Y stent. Case Reports in
Pulmonolgy 2014; 2014:709369.
11. Brandes C, Schmidt E, Yung R. Endobronchial stent placement as a
novel management approach to massive hemoptysis from lung
cancer. J Thorac Oncol 2008;3:1071-2.
12. Chung H, Park M, Kim DH, et al. Endobronchial stent insertion to
manage hemoptysis cause by cancer. J Korean Med Sci 2010;25:
1253-5.
pimeEDITRICE
No
n c
om
me
rci
al 
us
e o
nly
